Woyach J, et al. - In this phase 1b/2 trial, researchers evaluated acalabrutinib (a highly selective, potent, covalent Bruton tyrosine kinase inhibitor) with the CD20 antibody obinutuzumab in patients with treatment-naive or relapsed/refractory (≥1 prior therapy) chronic lymphocytic leukemia (CLL). Nineteen treatment-naive and 26 relapsed/refractory patients were administered acalabrutinib orally at 100 mg twice daily or 200 mg once daily (n = 15; all switched to 100 mg twice daily) in 28-day cycles, until progressive disease; they provided obinutuzumab in standard fashion for 6 cycles starting with Cycle 2. Patients showed good tolerability and high response rates that were durable and deepened over time using acalabrutinib plus obinutuzumab.